Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
212 Leser
Artikel bewerten:
(1)

Loftware, Inc.: Loftware Prisym 360 Version 1.16 Strengthens 'All-In-One' Clinical Trials Labeling Solution with New Features to Deliver Efficiencies and Simplify Compliance

Release Incorporates Clinical Data Connector and Randomization Module to Support End-To-End Management of Streamlined Clinical Labeling Processes

PORTSMOUTH, N.H., Oct. 26, 2022 /PRNewswire/ -- Loftware, the global leader in Enterprise Labeling and Artwork Management solutions, today announced the availability of Loftware Prisym 360 1.16. The latest release of Loftware's cloud-based clinical trials label and content management solution adds two new features designed to increase the efficiency of clinical trial supplies operations while reducing risk and simplifying compliance.

New Loftware logo

Prisym 360 1.16 introduces a new Clinical Data Connector, which streamlines the end-to-end clinical labeling process by connecting clinical supplies applications to Prisym 360's label and booklet design features. This removes the need for any label data to be input manually, helping to automate the process of GxP-compliant label printing and saving valuable user time while reducing the risks associated with manual inputs.

Supporting widely used industry protocols and standards, such as Web Services, SOAP, and REST, to maximize its compatibility with a customer's existing clinical supplies management applications, the Clinical Data Connector allows for the creation and revision of clinical trial master label data within Prisym 360. Consequently, a customer's existing clinical supplies application gains the ability to send print requests and associated data to Prisym 360 to produce labels on demand.

Additionally, Prisym 360 1.16 introduces a Randomization Module, which provides a comprehensive set of clinical label randomization functions that are fully integrated and available through a simple and intuitive user interface. Providing randomization functionality, especially valuable to organizations or teams without access to a RTSM application, the module has been designed in close collaboration with clinical supplies teams within several leading pharmaceutical R&D organizations and clinical supplies service providers. Through a step-by-step process, users can create randomization definitions to generate data for clinical trials packs while remaining fully integrated and compatible with Prisym 360's other clinical trials labeling functions, including the Clinical Data Connector and the 3-Step Clinical Label Print Process.

Both new features have been developed with direct input from existing users and are designed to support industry best practice. Due to the modular nature of Prisym 360, customers can flexibly upgrade their solution to access this new functionality if desired.

Simon Jones, Loftware VP Product Management, Life Sciences, said: "The pressure to reduce trial start-up times coupled with the growth in adaptive clinical trials has prompted focus amongst clinical supplies software application vendors to help streamline the end-to-end clinical trial supplies process. The Prisym 360 Clinical Data Connector, developed with input from best-of-breed Clinical Supplies Management vendors, such as Signant Health, helps simplify inter-connection with Prisym 360, thereby removing the need for manual data entry.

"Similarly, the new Randomization Module is designed to simplify the process of performing patient and kit-based randomization, as being integral within Prisym 360 aids with ease of use whilst helping customers ensure GxP compliance."

The Prisym 360 Clinical Data Connector and Data Randomization modules are now available as part of the latest 1.16 product release of Prisym 360. For more information, visit www.loftware.com

About Loftware:

Loftware?is the world's largest cloud-based Enterprise Labeling and Artwork Management provider, offering an end-to-end labeling solution platform for companies of all sizes. Maintaining a global presence with offices in the US, UK, Germany, Slovenia, China, and Singapore, Loftware boasts over 35 years of expertise in solving labeling challenges. We help companies improve accuracy, traceability and compliance while improving the quality, speed, and efficiency of their labeling. As the leading global provider of Enterprise Labeling and Artwork Management, along with Clinical Trials Labeling and Content Management, Loftware enables supply chain agility, supports evolving regulations, and optimizes business operations for a wide range of?industries. These include automotive, chemicals, consumer products, electronics, food & beverage, manufacturing, medical device, pharmaceuticals, retail and apparel.

Media contacts:
Laura Hindley, Senior PR & Communications Manager, lhindley@loftware.com

Logo - https://mma.prnewswire.com/media/1658239/Loftware_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/loftware-prisym-360-version-1-16-strengthens-all-in-one-clinical-trials-labeling-solution-with-new-features-to-deliver-efficiencies-and-simplify-compliance-301657275.html

© 2022 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.